KYMR FY 2024 Earnings — Kymera Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

KYMRKymera Therapeutics, Inc.

$7B

FY 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$47M-40.1% YoY

Gross Profit

$47M100.0% margin

Operating Income

-$262M-555.8% margin

Net Income

-$224M-475.6% margin

EPS (Diluted)

$-2.98

Cash Flow

Operating Cash Flow

-$195M

Free Cash Flow

-$207M

Stock-Based Comp.

$55M

Balance Sheet

Total Assets

$978M

Total Liabilities

$142M

Stockholders' Equity

$836M

Cash & Equivalents

$120M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$47M	$79M	-40.1%
Gross Profit	$47M	$79M	-40.1%
Operating Income	-$262M	-$166M	-58.1%
Net Income	-$224M	-$147M	-52.3%